Myelofibrosis Clinical Trials

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
U
An Optimal Dose Finding Study of N-Acetylcysteine in Patients With Myeloproliferative Neoplasms
Not yet recruiting
  • Myeloproliferative Neoplasm
  • +4 more
  • Orange, California
    Chao Family Comprehensive Cancer Center, University of Californi
2021-11-05
Nov 5, 2021
R
Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer
Recruiting
  • Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
  • +36 more
  • Buffalo, New York
    Roswell Park Cancer Institute
2021-11-16
Nov 16, 2021
N
Platform Study of Novel Ruxolitinib Combinations in Myelofibrosis Patients
Recruiting
  • Myelofibrosis
  • Adelaide, South Australia, Australia
  • +33 more
2021-11-15
Nov 15, 2021
I
To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)
Recruiting
  • Myelofibrosis
  • +3 more
  • Berkeley, California
  • +178 more
2021-11-10
Nov 10, 2021
F
European Registry for Myeloproliferative Neoplasms (MPNs) - Update of ERNEST Study
Active, not recruiting
  • Myelofibrosis
    • Firenze, FI, Italy
    • +5 more
    2021-11-11
    Nov 11, 2021
    I
    Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms
    Recruiting
    • Myelofibrosis
    • +5 more
    • Birmingham, Alabama
    • +9 more
    2021-11-10
    Nov 10, 2021
    G
    A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment
    Recruiting
    • Myelofibrosis
    • La Jolla, California
    • +164 more
    2021-11-08
    Nov 8, 2021
    B
    A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis)
    Recruiting
    • Myelofibrosis
    • La Jolla, California
    • +24 more
    2021-11-05
    Nov 5, 2021
    T
    Reduced-Intensity Conditioning for the Prevention of Treatment-Related Mortality in Patients Who Undergo a Hematopoietic Stem Cell Transplant
    Recruiting
    • Acute Lymphoblastic Leukemia
    • +15 more
    • Hematopoietic Cell Transplantation
    • +7 more
    • Philadelphia, Pennsylvania
      Sidney Kimmel Cancer Center at Thomas Jefferson University
    2021-11-02
    Nov 2, 2021
    U
    URMC Related Haplo-identical Donor BMT - 2021
    Completed
    • Hematological Disease
    • +5 more
    • Total Body Irradiation 1200 cGy
    • +9 more
    • Rochester, New York
      Wilmot Cancer Institute
    2021-11-01
    Nov 1, 2021
    I
    To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)
    Recruiting
    • Myelofibrosis
    • +3 more
    • Anchorage, Alaska
    • +153 more
    2021-11-01
    Nov 1, 2021
    G
    A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral GB2064 in Participants With Myelofibrosis
    Recruiting
    • Myelofibrosis
    • Houston, Texas
    • +11 more
    2021-10-28
    Oct 28, 2021
    S
    A Study of Oral TP-3654 in Patients With Myelofibrosis
    Recruiting
    • Myelofibrosis
    • Gainesville, Florida
    • +6 more
    2021-10-21
    Oct 21, 2021
    K
    An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With Ruxolitinib in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post ET-MF) Who Have a Suboptimal Response to Ruxolitinib
    Recruiting
    • Myelofibrosis
    • Duarte, California
    • +32 more
    2021-10-27
    Oct 27, 2021
    M
    Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases
    Recruiting
    • Acute Myeloid Leukemia (AML)
    • +17 more
    • Minneapolis, Minnesota
      University of Minnesota Masonic Cancer Center
    2021-10-27
    Oct 27, 2021
    C
    Study of CPI-0610 in Myelofibrosis (MF)
    Recruiting
    • Myelofibrosis
    • +3 more
    • La Jolla, California
    • +57 more
    2021-10-25
    Oct 25, 2021
    C
    An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions
    Recruiting
    • Myeloproliferative Disorders
    • +4 more
    • Birmingham, Alabama
    • +153 more
    2021-10-21
    Oct 21, 2021
    I
    A Rollover Study to Provide Continued Treatment for Participants Previously Enrolled in Studies of Itacitinib
    Recruiting
    • Myelofibrosis
    • Fort Wayne, Indiana
    • +2 more
    2021-10-13
    Oct 13, 2021
    T
    Safety and Early Efficacy Study of TBX-2400 in Patients With AML or Myelofibrosis
    Not yet recruiting
    • Myelofibrosis
    • Acute Myelogenous Leukemia
    • TBX-2400
    • Zagreb, Croatia
    • +1 more
    2021-10-04
    Oct 4, 2021
    P
    Study to Evaluate Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation and Expansion Study of PXS-5505 in Patients With Primary, Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis
    Recruiting
    • Myelofibrosis
    • Liverpool, New South Wales, Australia
    • +10 more
    2021-10-07
    Oct 7, 2021
    M
    Hu8F4 in Treating Patients With Advanced Hematologic Malignancies
    Recruiting
    • Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
    • +10 more
    • Anti-PR1/HLA-A2 Monoclonal Antibody Hu8F4
    • +2 more
    • Houston, Texas
      M D Anderson Cancer Center
    2021-09-30
    Sep 30, 2021
    M
    HA-1H TCR T Cell for Relapsed/Persistent Hematologic Malignancies After Allogeneic Stem Cell Transplantation
    Withdrawn
    • Acute Myeloid Leukemia
    • +7 more
    • MDG1021 dose 1
    • +3 more
    • Leiden, Zuid Holland, Netherlands
      Leiden University Medical Centre
    2021-09-30
    Sep 30, 2021
    N
    Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia
    Active, not recruiting
    • Acute Myeloid Leukemia
    • +9 more
    • Los Angeles, California
    • +5 more
    2021-09-29
    Sep 29, 2021
    I
    To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy (LIMBER-213)
    Recruiting
    • Myelofibrosis
    • +2 more
    • New Orleans, Louisiana
    • +14 more
    2021-09-27
    Sep 27, 2021
    S
    Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies - 2021
    Completed
    • Myelodysplastic Syndrome
    • +13 more
    • Baltimore, Maryland
      Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
    2021-09-24
    Sep 24, 2021